Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Monoethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360713 | 0.93 | POLB (0.49) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL688297 | 0.93 | POLB (0.49) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| Monoethanolamine SCHEMBL2890477 | 0.93 | POLB (0.49) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL2890329 | 0.91 | L3MBTL1 (0.39) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL2890322 | 0.91 | L3MBTL1 (0.39) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL2889307 | 0.89 | POLB (0.49) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| Triethylene Glycol SCHEMBL1361572 | 0.88 | EPHX2 (0.41) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| Glycerin SCHEMBL3844851 | 0.88 | POLB (0.45) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL14477954 | 0.85 | POLB (0.56) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL8084223 | 0.85 | POLB (0.56) | L3MBTL1POLBSMN1; SMN2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349215-B2 | Corrosion inhibitors having increased biological degradability and minimized toxicity | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-01-08 | — | — | US | disclosed |
| US-20120264611-A1 | Pesticide Preparations Containing Derivatives Of Pyrrolidone-4-Carboxylic Acid | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-10-18 | — | — | US | disclosed |
| US-20100283010-A1 | Corrosion Inhibitors Having Increased Biological Degradability And Minimized Toxicity | CLARIANT FINANCE (BVI) LIMITED (VG) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264611-A1 | Pesticide Preparations Containing Derivatives Of Pyrrolidone-4-Carboxylic Acid | DDT, HPD, AGPS | L3MBTL1 2904/4885POLB 3374/4885SMN1; SMN2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.